PT-141 (Bremelanotide)

From quiz to your door

Your provider will explain PT-141 in terms of where it acts, not what it does to blood flow. Bremelanotide, the active compound, is an alpha-MSH analog that activates MC3R and MC4R receptors in your hypothalamus, part of the desire and arousal circuitry your brain runs through dopamine and oxytocin. It works nothing like a PDE5 inhibitor: no vascular effect, no spontaneous arousal created from nothing. You still need arousal cues present for it to do anything. Because the mechanisms don't overlap, some patients are prescribed PT-141 alongside a PDE5 inhibitor rather than as a substitute for one, on your provider's guidance.

What the studies show

Bremelanotide is the active ingredient in Vyleesi, which the FDA approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its evidence base comes from the two randomized, placebo-controlled RECONNECT phase 3 trials. Use outside that approved group is off-label.

1. Kingsberg et al., Obstet Gynecol 2019 (RECONNECT phase 3 trials)
2. Simon et al., Obstet Gynecol 2019 (52-week safety extension)

Two different approaches

Two different mechanisms

Your first months

PT-141 is typically injected about 45 minutes before anticipated activity, with onset falling between 45 and 90 minutes and a window of effect lasting roughly 4 to 8 hours. The RECONNECT-1 and RECONNECT-2 trials, conducted in premenopausal women with hypoactive sexual desire disorder, found meaningful improvement in about 2 in 5 participants, compared with roughly 1 in 5 on placebo. Roughly 4 in 10 people using PT-141 experience nausea, most commonly in the two hours right after injecting, easing as treatment continues. Headache, a temporary blood pressure increase, injection-site reactions, and flushing round out the commonly reported effects, along with hyperpigmentation, skin, gum, or mole darkening that can develop with repeated use.

What to know about side effects

PT-141 is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Use for other purposes is off-label and not FDA-approved. This product is compounded by a licensed pharmacy and is not FDA-approved as dispensed. It has not undergone FDA review for safety or efficacy in that compounded form. PT-141 is off the table entirely if your blood pressure runs uncontrolled, or if bremelanotide has ever caused a hypersensitivity response for you. Your provider also factors in any history of cardiovascular disease, reduced liver or kidney function, and whether melanoma runs in your family or your own history, given the theoretical connection between the melanocortin pathway and melanoma risk. Because PT-141 can cause hyperpigmentation, darkening of the skin, gums, or moles, your provider will ask you to keep an eye on your moles and flag any changes. If your provider decides PT-141 isn't clinically appropriate for you, you won't be charged for the medication.